Anebulo Pharmaceuticals
OTC: ANEBLakeway, US · Founded 2020 · Delaware corporation · 1 known investors
Anebulo Pharmaceuticals is developing selonabant, a drug candidate intended to reverse cannabis-induced toxicities, including acute CNS depression in children and acute cannabinoid intoxication in adults. The company is a clinical-stage pharmaceutical developer targeting conditions for which there are no approved treatments.
BiotechHealthtechMedical Devices
Founders & leadership
Anebulo Pharmaceuticals was founded in 2020 by Joseph F. Lawler.
JF
Joseph F. LawlerFounder
RC
Richard CunninghamExecutive
DG
Daniel GeorgeExecutive
AE
Aron EnglishNamed on SEC filing
Board
JA
Jason AryehBoard director
AR
Aron R. EnglishBoard director
KL
Kenneth LinBoard director
AK
Areta KupchykBoard director
BS
Bimal ShahBoard director
NC
Nathaniel CallowayBoard director
Investors · 1
Competitors · 2
by search overlapRobinhood3 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha3 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Companies competing with Anebulo Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements$24.6M disclosed across 3 rounds · 2020–2024
▶$15MraisedDec 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$15MraisedDec 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Richard CunninghamExecutive Officer, Director
- Daniel GeorgeExecutive Officer
- Jason AryehDirector
- Aron R. EnglishDirector
- Kenneth LinDirector
- Joseph F. LawlerDirector
- Areta KupchykDirector
- Bimal ShahDirector
- Nathaniel CallowayDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$6.6MraisedOct 2022 · 5 investors · PharmaceuticalsRule 506(b)
▶$6.6MraisedOct 2022 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Areta KupchykDirector
- Joseph F. LawlerDirector
- Simon AllenExecutive Officer, Director
- Jason AryehDirector
- Kenneth LinDirector
- James R. MerchantExecutive Officer
- Karah ParschauerDirector
- Aron R. EnglishDirector
- Kenneth C. CundyExecutive Officer
- Offering amount
- $16.2M
- Amount sold
- $6.6M
- Sales commissions
- $150K
- Placement agents
- MTS Securities, LLC
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$3MraisedJun 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedJun 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Aron EnglishDirector
- Joseph F. LawlerExecutive Officer, Director
- Offering amount
- $5.3M
- Amount sold
- $3M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.